Skip to content
value.today

Precision IBD, Inc.

🇺🇸 Encinitas, California, USABiotechnologyFounded 2016
Total raised
$64 M
3 rounds on record
Latest round
$50 M
Oct 2020
First round on record
Sep 2017
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Precision IBD, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$50 MNo. 3$50 to $250 million

Precision IBD, Inc.: Raise no. 3, Oct 2020

Investors in this round

15 investors had bought by the notice of Nov 12, 2020: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Precision IBD, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $130 M offered; $80 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allison W. Luo, M.D. · Executive Officer
  • Keith W. Marshall, Ph.D. · Executive Officer
  • Lauren G. Otsuki · Executive Officer
  • Laurens W. Kruidenier, Ph.D. · Executive Officer
  • Mark Tachi McKenna · Executive Officer, Director
  • Adam C. Stone · Director
  • James D. Laur · Director
  • Joseph C. Papa · Director
  • Joy Ghosh, Ph.D. · Director
  • Martin Hendrix, Ph.D. · Director
  • Shierley C. Widjaja · Director
  • Tadataka Tachi Yamada, M.D. · Director
  • William C. Sandborn, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Keith Marshall, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Nov 12, 2020. Read the notice at the SEC.

equitySEC
Jun 2019$48 MIssued in a merger or acquisition$10 to $50 million

Precision IBD, Inc.: Private sale, Jun 2019

Investors in this round

11 investors had bought by the notice of Apr 10, 2020: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Precision IBD, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$48 M of $60 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allison Luo, M.D. · Executive Officer
  • Chris Slavinsky · Executive Officer
  • Lauren Otsuki · Executive Officer
  • Laurens Kruidenier, Ph.D. · Executive Officer
  • Mark Mckenna · Executive Officer, Director
  • Mike Walther · Executive Officer
  • Thierry Dervieux, Pharm D., Ph.D. · Executive Officer
  • Douglas Wall · Director
  • Gregory Behar · Director
  • James Laur · Director
  • Mark Stenhouse · Director
  • Shierley Widjaja · Director
  • Shlomo Melmed · Director
  • Tadataka Yamada, M.D. · Director
  • William Sandborn, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chris Slavinsky, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Apr 10, 2020. Read the notice at the SEC.

equitySEC
Nov 2018$10 MNo. 2$10 to $50 million

Precision IBD, Inc.: Raise no. 2, Nov 2018

Investors in this round

22 investors had bought by the notice of Nov 28, 2018: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Precision IBD, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott L. Glenn · Executive Officer, Director
  • Douglas F. Wall · Director
  • Gerald T. Proehl · Director
  • Mark T. Stenhouse · Director
  • Rolf J. Benirschke · Director
  • Shlomo T. Melmed · Director
  • Stephan T. Targan · Director
  • Tadataka T. Yamada · Director
  • William F. Sandborn, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott L. Glenn, President and CEO. Source: SEC Form D, newest notice filed Nov 28, 2018. Read the notice at the SEC.

equitySEC
Sep 2017$4 MNo. 1$2 to $10 million

Precision IBD, Inc.: Raise no. 1, Sep 2017

Investors in this round

22 investors had bought by the notice of Oct 10, 2017: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Precision IBD, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $10 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott L. Glenn · Executive Officer, Director
  • Douglas F. Wall · Director
  • Rolf J. Benirschke · Director
  • William F. Sandborn, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott L. Glenn, President and CEO. Source: SEC Form D, newest notice filed Oct 10, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Precision IBD, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2020

That is all the official record says: Precision IBD, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Precision IBD, Inc.
InvestorKindAmountRoundRoleSource
72 Investment Holdings, LLCFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cedars Sinai Medical CenterPersonnot statednot statedHeld Series A, B, C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cohen Steven A/sac Capital Mgmt LPFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Differentiated Ventures Investments, LLCVenture capitalnot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Nestle SACompanynot statednot statedHeld Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Perceptive Advisors LLCFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Perceptive Life Sciences Master Fund LTDFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Point72 Biotech Private Investments, LLCFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RTW Investments, LPFund or asset managernot statednot statedHeld Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Societe des Produits Nestle S.A.Companynot statednot statedHeld Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Tadataka YamadaPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Precision IBD, Inc.
NameRoleNamed in
Allison W. Luo, M.D.Executive officerNov 2020
Keith W. Marshall, Ph.D.Executive officerNov 2020
Lauren G. OtsukiExecutive officerNov 2020
Laurens W. Kruidenier, Ph.D.Executive officerNov 2020
Mark Tachi McKennaExecutive officerNov 2020
Allison Luo, M.D.Executive officerApr 2020
Chris SlavinskyExecutive officerApr 2020
Lauren OtsukiExecutive officerApr 2020
Laurens Kruidenier, Ph.D.Executive officerApr 2020
Mark MckennaExecutive officerApr 2020
Mike WaltherExecutive officerApr 2020
Thierry Dervieux, Pharm D., Ph.D.Executive officerApr 2020
Scott L. GlennExecutive officerJul 2019
Adam C. StoneDirectorNov 2020
James D. LaurDirectorNov 2020
Joseph C. PapaDirectorNov 2020
Joy Ghosh, Ph.D.DirectorNov 2020
Mark Tachi McKennaDirectorNov 2020
Martin Hendrix, Ph.D.DirectorNov 2020
Shierley C. WidjajaDirectorNov 2020
Tadataka Tachi Yamada, M.D.DirectorNov 2020
William C. Sandborn, M.D.DirectorNov 2020
Douglas WallDirectorApr 2020
Gregory BeharDirectorApr 2020
James LaurDirectorApr 2020
Mark MckennaDirectorApr 2020
Mark StenhouseDirectorApr 2020
Shierley WidjajaDirectorApr 2020
Shlomo MelmedDirectorApr 2020
Tadataka Yamada, M.D.DirectorApr 2020
William Sandborn, M.D.DirectorApr 2020
Douglas F. WallDirectorJul 2019
Gerald T. ProehlDirectorJul 2019
Gregory L. BeharDirectorJul 2019
Mark T. StenhouseDirectorJul 2019
Scott L. GlennDirectorJul 2019
Shierley T. WidjajaDirectorJul 2019
Shlomo T. MelmedDirectorJul 2019
Tadataka T. Yamada, M.D.DirectorJul 2019
William F. Sandborn, M.D.DirectorJul 2019